Chuanliang Cui

Peking University - Key Laboratory of Carcinogenesis and Translational Research

No. 38 Xueyuan Road

Haidian District

Beijing, Beijing 100871

China

SCHOLARLY PAPERS

2

DOWNLOADS

310

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

Efficacy and Safety of RC48-ADC, a Her2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase 2, Open-Label, Multi-Centre, Single-Arm Study

Number of pages: 118 Posted: 02 Oct 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology, Sun Yat-sen University (SYSU) - Department of Medical Oncology, Tianjin Medical University, Chongqing University, Shandong University - Qilu Hospital, Sichuan University - Department of Medical Oncology, Peking University - Department of Urology, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Pathology, Central South University - Affiliated Cancer Hospital, Anhui Provincial Cancer Hospital, Chinese Academy of Medical Sciences - National Cancer Center, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, RemeGen, Ltd., Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 193 (328,733)
Citation 1

Abstract:

Loading...

2.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 117 (498,094)
Citation 1

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib